Marino Garcia, CEO of Dianthus Therapeutics, will participate in fireside chats and host one-on-one investor meetings at the following conferences: Guggenheim 2nd Annual Healthcare Innovation ...

Dianthus Therapeutics is on a mission to reduce the number of injections autoimmune disease patients have to receive, using $100 million in series A financing to send its antibody candidate into the ...

Dianthus Therapeutics ( ($DNTH) ) just unveiled an announcement. On November 3, 2025, Dianthus Therapeutics updated its corporate presentation, ...

Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data ...

Dianthus Therapeutics is advancing its challenge for the increasingly competitive generalized myasthenia gravis (gMG) market, outlining plans to move into phase 3 on the back of hits in a midphase ...

We recently published 10 Stocks With Eye-Popping Gains; 7 Soar to Fresh Highs. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is one of the top performers on Monday. Dianthus Therapeutics soared to a new ...

Dianthus Therapeutics Inc. has joined the recent trend of companies licensing therapies in development from China. The ...

References to the plant genus Dianthus go back as far as the Greek botanist Theophrastus. He named these plants from the Caryophyllaceae family “divine flower” (dios = divine plus anthos = flower).

Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing Phase ...